NASDAQ:SLNO Soleno Therapeutics (SLNO) Stock Price, News & Analysis → The Military's $700M 'AI Software Bullet' (From Behind the Markets) (Ad) Free SLNO Stock Alerts $42.49 +0.08 (+0.19%) (As of 05:33 PM ET) Add Compare Share Share Today's Range$41.49▼$42.7250-Day Range$37.14▼$49.2352-Week Range$3.69▼$53.82Volume733,285 shsAverage Volume361,461 shsMarket Capitalization$1.42 billionP/E RatioN/ADividend YieldN/APrice Target$60.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Soleno Therapeutics alerts: Email Address Soleno Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.14 Rating ScoreUpside/Downside42.0% Upside$60.33 Price TargetShort InterestBearish16.04% of Float Sold ShortDividend StrengthN/ASustainability-0.55Upright™ Environmental ScoreNews Sentiment1.30Based on 2 Articles This WeekInsider TradingSelling Shares$36.94 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.36) to ($2.42) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.84 out of 5 starsMedical Sector185th out of 913 stocksElectromedical Equipment Industry3rd out of 19 stocks 3.6 Analyst's Opinion Consensus RatingSoleno Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.14, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageSoleno Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Soleno Therapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted16.04% of the float of Soleno Therapeutics has been sold short.Short Interest Ratio / Days to CoverSoleno Therapeutics has a short interest ratio ("days to cover") of 8.3.Change versus previous monthShort interest in Soleno Therapeutics has recently increased by 6.92%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldSoleno Therapeutics does not currently pay a dividend.Dividend GrowthSoleno Therapeutics does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreSoleno Therapeutics has received a 73.45% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for genetic diseases" and "Basic medical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Soleno Therapeutics is -0.55. Previous Next 2.9 News and Social Media Coverage News SentimentSoleno Therapeutics has a news sentiment score of 1.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.92 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Soleno Therapeutics this week, compared to 2 articles on an average week.Search Interest1 people have searched for SLNO on MarketBeat in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Soleno Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $36,940,260.00 in company stock.Percentage Held by Insiders12.30% of the stock of Soleno Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions97.42% of the stock of Soleno Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Soleno Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Soleno Therapeutics are expected to decrease in the coming year, from ($2.36) to ($2.42) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Soleno Therapeutics is -15.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Soleno Therapeutics is -15.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSoleno Therapeutics has a P/B Ratio of 8.23. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Soleno Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Prosper Trading AcademyThis AI made her leave her jobThis AI trading tool is probably unlike anything you've ever seen before… It scans the entire market and finds hot stocks that you probably have never even heard of… …it recommends the best potential strategy to use on the names it finds (with historical data to prove it)Click Here To Read More About This Game Changing AI Tool About Soleno Therapeutics Stock (NASDAQ:SLNO)Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.Read More SLNO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SLNO Stock News HeadlinesJune 7, 2024 | americanbankingnews.comSoleno Therapeutics (NASDAQ:SLNO) Trading 5.8% Higher June 7, 2024 | americanbankingnews.comSoleno Therapeutics, Inc. (NASDAQ:SLNO) Receives $60.33 Average PT from AnalystsJune 6, 2024 | 247wallst.com3 Stocks That Have Seen Higher Share Gains Than Super Micro ComputerMay 22, 2024 | globenewswire.comSoleno Therapeutics Announces Oral Presentation featuring DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome at ENDO 2024May 22, 2024 | globenewswire.comSoleno Therapeutics to Participate in Upcoming Investor ConferencesMay 15, 2024 | globenewswire.comSoleno Therapeutics Stands with the Prader-Willi Syndrome CommunityMay 13, 2024 | markets.businessinsider.comSoleno Therapeutics (SLNO) Receives a Buy from Stifel NicolausMay 11, 2024 | msn.comBaird Initiates Coverage of Soleno Therapeutics (SLNO) with Outperform RecommendationMay 10, 2024 | investorplace.comSLNO Stock Earnings: Soleno Therapeutics Misses EPS for Q1 2024May 9, 2024 | markets.businessinsider.comSoleno Therapeutics’ DCCR Poised for FDA Approval and Blockbuster Sales: An Analyst’s Bullish OutlookMay 9, 2024 | globenewswire.comSoleno Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial ResultsMay 8, 2024 | finance.yahoo.comWhile institutions invested in Soleno Therapeutics, Inc. (NASDAQ:SLNO) benefited from last week's 4.8% gain, private equity firms stood to gain the mostMay 3, 2024 | nasdaq.comSoleno Therapeutics Prices Public Offering Of 3 Mln Shares At $46/shr; Stock Down In After-hoursMay 2, 2024 | globenewswire.comSoleno Therapeutics Announces Pricing of Approximately $138 Million Public Offering Of Common StockMay 2, 2024 | globenewswire.comSoleno Therapeutics Announces Proposed Public Offering of Common StockApril 30, 2024 | globenewswire.comSoleno Therapeutics Announces Peer-Reviewed Publication of Data Comparing DCCR Treatment to the Natural History of Prader-Willi SyndromeApril 29, 2024 | marketwatch.comSoleno Therapeutics Gets Breakthrough Therapy Designation for Diazoxide CholineApril 29, 2024 | marketwatch.comSoleno Therapeutics Shares Rise 37% After Breakthrough Designation for Diazoxide CholineApril 29, 2024 | seekingalpha.comSoleno: Mid-2024 NDA Filing For PWS Treatment Is A Major Catalyst To WatchApril 29, 2024 | fool.comWhy Soleno Therapeutics Stock Is Skyrocketing TodayApril 29, 2024 | globenewswire.comSoleno Therapeutics Receives Breakthrough Therapy Designation from U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome (PWS)April 19, 2024 | globenewswire.comSoleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 5, 2024 | investing.comSoleno Therapeutics CEO sells over $780k in company stockApril 4, 2024 | finance.yahoo.comInsider Sell: CFO James Mackaness Sells 5,175 Shares of Soleno Therapeutics Inc (SLNO)April 4, 2024 | finance.yahoo.comCEO Bhatnagar Anish Sells 18,980 Shares of Soleno Therapeutics Inc (SLNO)See More Headlines Receive SLNO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Soleno Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today6/17/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Electromedical equipment Sub-IndustryN/A Current SymbolNASDAQ:SLNO CUSIPN/A CIK1484565 Webwww.soleno.life Phone(650) 213-8444Fax650-213-8383Employees33Year FoundedN/APrice Target and Rating Average Stock Price Target$60.33 High Stock Price Target$93.00 Low Stock Price Target$35.00 Potential Upside/Downside+43.4%Consensus RatingBuy Rating Score (0-4)3.14 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($2.68) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-38,990,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-61.84% Return on Assets-46.87% Debt Debt-to-Equity RatioN/A Current Ratio11.23 Quick Ratio11.23 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.16 per share Price / Book8.16Miscellaneous Outstanding Shares33,410,000Free Float29,301,000Market Cap$1.41 billion OptionableOptionable Beta-1.40 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesDr. Anish Bhatnagar M.D. (Age 54)President, CEO, COO & Director Comp: $1.06MMr. James H. MacKaness (Age 60)Chief Financial Officer Comp: $640kMs. Patricia C. Hirano M.P.H. (Age 58)Senior Vice President of Regulatory Affairs Comp: $493kMs. Lauren BudesheimVice President of PeopleMs. Kristen Yen M.S. (Age 55)Senior Vice President of Clinical Operations Comp: $317.19kDr. Neil M. Cowen M.B.A.Ph.D., Senior Vice President of Drug DevelopmentMs. Meredith Manning M.B.A. (Age 52)Chief Commercial Officer Dr. Michael Huang M.D. (Age 50)Senior Vice President of Clinical Development More ExecutivesKey CompetitorsRhythm PharmaceuticalsNASDAQ:RYTMLarimar TherapeuticsNASDAQ:LRMRRockwell MedicalNASDAQ:RMTITransMedics GroupNASDAQ:TMDXIntegerNYSE:ITGRView All CompetitorsInsiders & InstitutionsFarallon Capital Management LLCSold 137,469 shares on 5/24/2024Ownership: 0.083%Janus Henderson Group PLCBought 346,914 shares on 5/16/2024Ownership: 8.593%California State Teachers Retirement SystemBought 3,481 shares on 5/16/2024Ownership: 0.041%Avoro Capital Advisors LLCBought 840,000 shares on 5/15/2024Ownership: 4.864%Price T Rowe Associates Inc. MDBought 152,620 shares on 5/15/2024Ownership: 0.457%View All Insider TransactionsView All Institutional Transactions SLNO Stock Analysis - Frequently Asked Questions Should I buy or sell Soleno Therapeutics stock right now? 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Soleno Therapeutics in the last twelve months. There are currently 6 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SLNO shares. View SLNO analyst ratings or view top-rated stocks. What is Soleno Therapeutics' stock price target for 2024? 7 brokers have issued 12-month price objectives for Soleno Therapeutics' stock. Their SLNO share price targets range from $35.00 to $93.00. On average, they anticipate the company's stock price to reach $60.33 in the next twelve months. This suggests a possible upside of 42.0% from the stock's current price. View analysts price targets for SLNO or view top-rated stocks among Wall Street analysts. How have SLNO shares performed in 2024? Soleno Therapeutics' stock was trading at $40.25 on January 1st, 2024. Since then, SLNO stock has increased by 5.6% and is now trading at $42.49. View the best growth stocks for 2024 here. When is Soleno Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024. View our SLNO earnings forecast. How were Soleno Therapeutics' earnings last quarter? Soleno Therapeutics, Inc. (NASDAQ:SLNO) released its earnings results on Thursday, May, 9th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by $0.29. What ETFs hold Soleno Therapeutics' stock? ETFs with the largest weight of Soleno Therapeutics (NASDAQ:SLNO) stock in their portfolio include Invesco DWA SmallCap Momentum ETF (DWAS), Virtus LifeSci Biotech Clinical Trials ETF (BBC), ALPS Medical Breakthroughs ETF (SBIO) and Tema Cardiovascular and Metabolics ETF (HRTS). When did Soleno Therapeutics' stock split? Soleno Therapeutics's stock reverse split on Friday, August 26th 2022. The 1-15 reverse split was announced on Friday, August 26th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 26th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. What other stocks do shareholders of Soleno Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Soleno Therapeutics investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), SCYNEXIS (SCYX), OPKO Health (OPK), ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Miragen Therapeutics (MGEN), Vaxart (VXRT), Dynavax Technologies (DVAX) and TherapeuticsMD (TXMD). Who are Soleno Therapeutics' major shareholders? Soleno Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Carlyle Group Inc. (12.19%), Janus Henderson Group PLC (8.59%), Avoro Capital Advisors LLC (4.86%), Price T Rowe Associates Inc. MD (0.46%), StemPoint Capital LP (0.35%) and Allspring Global Investments Holdings LLC (0.31%). Insiders that own company stock include Bhatnagar Anish, Jack W Schuler, James H Mackaness, Kristen Yen, Perceptive Advisors Llc and Vivo Opportunity, Llc. View institutional ownership trends. How do I buy shares of Soleno Therapeutics? Shares of SLNO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SLNO) was last updated on 6/17/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredBigger Than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout stock. But right now... There's only ...Behind the Markets | SponsoredThis AI made her leave her jobThis AI trading tool is probably unlike anything you've ever seen before… It scans the entire market and fi...Prosper Trading Academy | SponsoredRadical change coming — do this NOW to protect yourselfI recently uncovered a way the government could use the next crisis as a pretext to gain more control … and ra...Weiss Ratings | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredInflation Is Robbing You Blind! Here’s How to Fight Back!Quietly, inflation has reduced your purchasing power by 29.4% since 2014. So something that cost $100 in 20...American Alternative | SponsoredBiden Nomination CANCELED?And I believe when they do take the oath of office, their fingers will be crossed… and America will descend in...The Freeport Society | SponsoredElon’s New Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Soleno Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Soleno Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
